Abstract
Neurexin 1 (NRXN1), a presynaptic cell adhesion molecule, is implicated in several neurodevelopmental disorders characterized by synaptic dysfunction including autism, intellectual disability and schizophrenia. To gain insight into NRXN1’s involvement in human cortical development we used quantitative real-time PCR to examine the expression trajectories of NRXN1, and its predominant isoforms, NRXN1-α and NRXN1-β, in prefrontal cortex from fetal stages to aging. In addition, we investigated whether prefrontal cortical expression levels of NRXN1 transcripts are altered in schizophrenia or bipolar disorder in comparison with non-psychiatric control subjects. We observed that all three NRXN1 transcripts were highly expressed during human fetal cortical development, markedly increasing with gestational age. In the postnatal dorsolateral prefrontal cortex, expression levels were negatively correlated with age, peaking at birth until ~3 years of age, after which levels declined markedly to be stable across the lifespan. NRXN1-β expression was modestly but significantly elevated in the brains of patients with schizophrenia compared with non-psychiatric controls, whereas NRXN1-α expression was increased in bipolar disorder. These data provide novel evidence that NRXN1 expression is highest in human dorsolateral prefrontal cortex during critical developmental windows relevant to the onset and diagnosis of a range of neurodevelopmental disorders, and that NRXN1 expression may be differentially altered in neuropsychiatric disorders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Autism Genome Project C, Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 2007; 39: 319–328.
Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008; 82: 477–488.
Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 2009; 459: 569–573.
Bena F, Bruno DL, Eriksson M, van Ravenswaaij-Arts C, Stark Z, Dijkhuizen T et al. Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature. Am J Med Genet 2013; 162B: 388–403.
Ching MS, Shen Y, Tan WH, Jeste SS, Morrow EM, Chen X et al. Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am J Med Genet 2010; 153B: 937–947.
Gregor A, Albrecht B, Bader I, Bijlsma EK, Ekici AB, Engels H et al. Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1. BMC Med Genet 2011; 12: 106.
Tucker T, Zahir FR, Griffith M, Delaney A, Chai D, Tsang E et al. Single exon-resolution targeted chromosomal microarray analysis of known and candidate intellectual disability genes. Eur J Hum Genet 2014; 22: 792–800.
Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 2008; 17: 458–465.
Ikeda M, Aleksic B, Kirov G, Kinoshita Y, Yamanouchi Y, Kitajima T et al. Copy number variation in schizophrenia in the Japanese population. Biol Pyschiatry 2010; 67: 283–286.
International Schizophrenia C. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008; 455: 237–241.
Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009; 17: 946–957.
Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Toulopoulou T et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 2009; 18: 988–996.
Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E et alGenetic R, Outcome in Psychosis C. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet 2008; 83: 504–510.
Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008; 320: 539–543.
Todarello G, Feng N, Kolachana BS, Li C, Vakkalanka R, Bertolino A et al. Incomplete penetrance of NRXN1 deletions in families with schizophrenia. Schizophr Res 2014; 155: 1–7.
Souza RP, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL . Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Hum Psychopharmacol 2010; 25: 582–585.
Lett TA, Tiwari AK, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN et al. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophr Res 2011; 132: 121–124.
Jenkins A, Apud JA, Zhang F, Decot H, Weinberger DR, Law AJ . Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia. Neuropsychopharmacology 2014; 39: 2170–2178.
Tansey KE, Rucker JJ, Kavanagh DH, Guipponi M, Perroud N, Bondolfi G et al. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics J 2014; 14: 395–399.
Nussbaum J, Xu Q, Payne TJ, Ma JZ, Huang W, Gelernter J et al. Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. Hum Mol Genet 2008; 17: 1569–1577.
Yang J, Wang S, Yang Z, Hodgkinson CA, Iarikova P, Ma JZ et al. The contribution of rare and common variants in 30 genes to risk nicotine dependence. Mol Psychiatry 2014; doi:10.1038/mp.2014.156; e-pub ahead of print.
Rowen L, Young J, Birditt B, Kaur A, Madan A, Philipps DL et al. Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics 2002; 79: 587–597.
Missler M, Sudhof TC . Neurexins: three genes and 1001 products. Trends Genet 1998; 14: 20–26.
Tabuchi K, Sudhof TC . Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing. Genomics 2002; 79: 849–859.
Sudhof TC . Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008; 455: 903–911.
Graf ER, Zhang X, Jin SX, Linhoff MW, Craig AM . Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell 2004; 119: 1013–1026.
Song JY, Ichtchenko K, Sudhof TC, Brose N . Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses. Proc Natl Acad Sci USA 1999; 96: 1100–1105.
Varoqueaux F, Jamain S, Brose N . Neuroligin 2 is exclusively localized to inhibitory synapses. Eur J Cell Biol 2004; 83: 449–456.
Boucard AA, Chubykin AA, Comoletti D, Taylor P, Sudhof TC . A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexins. Neuron 2005; 48: 229–236.
Zhang C, Atasoy D, Arac D, Yang X, Fucillo MV, Robison AJ et al. Neurexins physically and functionally interact with GABA(A) receptors. Neuron 2010; 66: 403–416.
Sun C, Cheng MC, Qin R, Liao DL, Chen TT, Koong FJ et al. Identification and functional characterization of rare mutations of the neuroligin-2 gene (NLGN2) associated with schizophrenia. Hum Mol Genet 2011; 20: 3042–3051.
Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003; 34: 27–29.
Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci USA 2006; 103: 6747–6752.
Kao WT, Wang Y, Kleinman JE, Lipska BK, Hyde TM, Weinberger DR et al. Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain. Proc Natl Acad Sci USA 2010; 107: 15619–15624.
Andersen SL . Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 2003; 27: 3–18.
Tau GZ, Peterson BS . Normal development of brain circuits. Neuropsychopharmacology 2010; 35: 147–168.
Huttenlocher PR . Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res 1979; 163: 195–205.
Puschel AW, Betz H . Neurexins are differentially expressed in the embryonic nervous system of mice. J Neurosci 1995; 15: 2849–2856.
Paraoanu LE, Becker-Roeck M, Christ E, Layer PG . Expression patterns of neurexin-1 and neuroligins in brain and retina of the chick embryo: Neuroligin-3 is absent in retina. Neurosci Lett 2006; 395: 114–117.
Brown SM, Clapcote SJ, Millar JK, Torrance HS, Anderson SM, Walker R et al. Synaptic modulators Nrxn1 and Nrxn3 are disregulated in a Disc1 mouse model of schizophrenia. Mol Psychiatry 2011; 16: 585–587.
Rozic-Kotliroff G, Zisapel N . Ca2+ -dependent splicing of neurexin IIalpha. Biochem Biophys Res Commun 2007; 352: 226–230.
Iijima T, Wu K, Witte H, Hanno-Iijima Y, Glatter T, Richard S et al. SAM68 regulates neuronal activity-dependent alternative splicing of neurexin-1. Cell 2011; 147: 1601–1614.
Rozic G, Lupowitz Z, Piontkewitz Y, Zisapel N . Dynamic changes in neurexins' alternative splicing: role of Rho-associated protein kinases and relevance to memory formation. PloS One 2011; 6: e18579.
Kang Y, Zhang X, Dobie F, Wu H, Craig AM . Induction of GABAergic postsynaptic differentiation by alpha-neurexins. J Biol Chem 2008; 283: 2323–2334.
Chih B, Gollan L, Scheiffele P . Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin complex. Neuron 2006; 51: 171–178.
Graf ER, Kang Y, Hauner AM, Craig AM . Structure function and splice site analysis of the synaptogenic activity of the neurexin-1 beta LNS domain. J Neurosci 2006; 26: 4256–4265.
Siddiqui TJ, Pancaroglu R, Kang Y, Rooyakkers A, Craig AM . LRRTMs and neuroligins bind neurexins with a differential code to cooperate in glutamate synapse development. J Neurosci 2010; 30: 7495–7506.
Kumar D, Thakur MK . Perinatal exposure to bisphenol-A impairs spatial memory through upregulation of neurexin1 and neuroligin3 expression in male mouse brain. PloS One 2014; 9: e110482.
Noor A, Lionel AC, Cohen-Woods S, Moghimi N, Rucker J, Fennell A et al. Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes. Am J Med Genet 2014; 165B: 303–313.
International Schizophrenia C, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748–752.
Acknowledgements
This research was supported primarily by funds from the National Institutes of Health, National Institute of Mental Health intramural program to the Law lab and Clinical Brain Disorders Branch, and in part by NIH, R01MH103716 (Law PI). We would like to acknowledge Dr Daniel Weinberger, for additional research support from the Clinical Brain Disorders Branch and Amy Deep-Soboslay of the National Institutes of Health, National Institute of Mental Health and Lieber Institute for Brain Development for efforts in demographic characterization.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Molecular Psychiatry website
Rights and permissions
About this article
Cite this article
Jenkins, A., Paterson, C., Wang, Y. et al. Neurexin 1 (NRXN1) splice isoform expression during human neocortical development and aging. Mol Psychiatry 21, 701–706 (2016). https://doi.org/10.1038/mp.2015.107
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/mp.2015.107
This article is cited by
-
An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data
Molecular Psychiatry (2022)
-
RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma
Cellular Oncology (2021)
-
The Prevailing Role of Topoisomerase 2 Beta and its Associated Genes in Neurons
Molecular Neurobiology (2021)
-
Genetic insights and neurobiological implications from NRXN1 in neuropsychiatric disorders
Molecular Psychiatry (2019)
-
Neuronal impact of patient-specific aberrant NRXN1α splicing
Nature Genetics (2019)